Arkema

Sustained profitability despite lower sales prices

14/05/24 -"Sales in the Q1 declined as anticipated, but adjusted EBITDA demonstrated greater resilience. The figures were mixed compared to the consensus (sales: -2.0%; adjusted EBITDA: +2.6%; adjusted EPS: ..."

PDF page sample
Pages
66
Language
English
Published on
14/05/24
Download
You may also be interested by these reports :
28/08/26
2026: The increase is largely attributed to lower operational expenses in Q2 resulting in an upward revision of our estimate for adj. EBIT to €153m ...
28/08/26
We are raising our FY26 EPS estimate by 12%, mainly reflecting the stronger operating earnings outlook following the Q2 performance and the upgrade ...
27/08/26
Givaudan utilised its Summer Investor Conference to reaffirm its 2030 financial ambitions and refine its strategy under the new CEO. The adjustments ...
25/08/26
The decline in EPS is due to a slight increase in shares outstanding.

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO